Skip to content

Erasca, Inc. ERAS Other Income (Expense)

Other Income (Expense) at other companies

Eli Lilly logo
Eli LillyLLY
-$65M+72.8%
Amgen logo
AmgenAMGN
$75M-95.1%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$8.59M-131%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$3.26M+21.1%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$10.01M-18.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$6M-40.0%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s other income (expense)?
Erasca, Inc. (ERAS) reported other income (expense) of $4.47M in Q1 2026.
How has Erasca, Inc.'s other income (expense) changed year-over-year?
Erasca, Inc.'s other income (expense) decreased by 4.1% year-over-year, from $4.66M to $4.47M.
What is the long-term trend for Erasca, Inc.'s other income (expense)?
Over 4 years (2021 to 2025), Erasca, Inc.'s other income (expense) has grown at a 66.7% compound annual growth rate (CAGR), from $2.12M to $16.36M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.